Sanofi-aventis, Intelliject sign an exclusive licensing agreement for novel epinephrine auto injector

Sanofi-aventis U.S. announced today the signing of an exclusive licensing agreement with Intelliject, Inc. for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis) in North America (U.S. and Canada).

"We are pleased to have this opportunity to offer this innovative delivery device for the millions of people who are at risk of this life-threatening allergic reaction each year," stated Brent Ragans, Vice President, Head of General Therapeutics, sanofi-aventis U.S. "This agreement complements our strong presence in the U.S. as a leader in the allergy arena and is a great example of our company's transformation into a provider of healthcare solutions."

Sanofi-aventis will be responsible for manufacturing and commercial activities in North America. Intelliject will be responsible for the on-going development and regulatory submission in the U.S. In addition, Intelliject has retained certain rights to co-promote the product in the U.S.

Under the terms of the agreement, sanofi-aventis U.S. will make an upfront payment and Intelliject will be eligible for future milestone payments and royalties on product sales.